IBDEI1A3 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21741,1,3,0)
 ;;=3^Acute Lymphangitis of Right Toe
 ;;^UTILITY(U,$J,358.3,21741,1,4,0)
 ;;=4^L03.041
 ;;^UTILITY(U,$J,358.3,21741,2)
 ;;=^5009028
 ;;^UTILITY(U,$J,358.3,21742,0)
 ;;=L03.042^^87^970^20
 ;;^UTILITY(U,$J,358.3,21742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21742,1,3,0)
 ;;=3^Acute Lymphangitis of Left Toe
 ;;^UTILITY(U,$J,358.3,21742,1,4,0)
 ;;=4^L03.042
 ;;^UTILITY(U,$J,358.3,21742,2)
 ;;=^5009029
 ;;^UTILITY(U,$J,358.3,21743,0)
 ;;=M34.0^^87^970^249
 ;;^UTILITY(U,$J,358.3,21743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21743,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,21743,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,21743,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,21744,0)
 ;;=M34.1^^87^970^91
 ;;^UTILITY(U,$J,358.3,21744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21744,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,21744,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,21744,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,21745,0)
 ;;=M34.2^^87^970^273
 ;;^UTILITY(U,$J,358.3,21745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21745,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,21745,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,21745,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,21746,0)
 ;;=M34.81^^87^970^275
 ;;^UTILITY(U,$J,358.3,21746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21746,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,21746,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,21746,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,21747,0)
 ;;=M34.82^^87^970^276
 ;;^UTILITY(U,$J,358.3,21747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21747,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,21747,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,21747,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,21748,0)
 ;;=M34.83^^87^970^277
 ;;^UTILITY(U,$J,358.3,21748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21748,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,21748,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,21748,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,21749,0)
 ;;=M34.89^^87^970^274
 ;;^UTILITY(U,$J,358.3,21749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21749,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,21749,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,21749,2)
 ;;=^5011784
 ;;^UTILITY(U,$J,358.3,21750,0)
 ;;=M34.9^^87^970^278
 ;;^UTILITY(U,$J,358.3,21750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21750,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,21750,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,21750,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,21751,0)
 ;;=R21.^^87^970^257
 ;;^UTILITY(U,$J,358.3,21751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21751,1,3,0)
 ;;=3^Rash/Nonspecific Skin Eruption
 ;;^UTILITY(U,$J,358.3,21751,1,4,0)
 ;;=4^R21.
 ;;^UTILITY(U,$J,358.3,21751,2)
 ;;=^5019283
 ;;^UTILITY(U,$J,358.3,21752,0)
 ;;=R23.3^^87^970^269
 ;;^UTILITY(U,$J,358.3,21752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21752,1,3,0)
 ;;=3^Spontaneous Ecchymoses
 ;;^UTILITY(U,$J,358.3,21752,1,4,0)
 ;;=4^R23.3
 ;;^UTILITY(U,$J,358.3,21752,2)
 ;;=^5019295
 ;;^UTILITY(U,$J,358.3,21753,0)
 ;;=L03.113^^87^970^112
 ;;^UTILITY(U,$J,358.3,21753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21753,1,3,0)
 ;;=3^Cellulitis of Right Upper Limb
 ;;^UTILITY(U,$J,358.3,21753,1,4,0)
 ;;=4^L03.113
 ;;^UTILITY(U,$J,358.3,21753,2)
 ;;=^5009033
 ;;^UTILITY(U,$J,358.3,21754,0)
 ;;=L03.114^^87^970^105
 ;;^UTILITY(U,$J,358.3,21754,1,0)
 ;;=^358.31IA^4^2
